HK Stock Market Move | METIS TECHBIO-P(07666) rose more than 11% in early trading. It took only half a year for MTS-128 to go from PCC to completion of BD.

METIS TECHBIO-P(07666) rose by over 11% in early trading, and as of the time of writing, it has risen by 9% to 11.63 Hong Kong dollars with a turnover of 52.73 million Hong Kong dollars. On the news front, Jitai Technology recently announced a global exclusive cooperation agreement with Boulevard, a subsidiary of Deerfield, for MTS-128. Jitai Technology will receive a upfront payment of 20 million US dollars, up to 1.6 billion US dollars in milestone payments, and potential sales royalties. This is the largest authorization transaction for a preclinical TCE project in China. China Securities Co., Ltd. pointed out that MTS-128 from PCC to completion of BD took only six months, verifying the company's efficient landing ability of the "platform cooperation + product cooperation" dual-wheel driven business model. MTS-128 is a three specific TCE developed and optimized by NanoForge platform AiProtein. With the continuous output of high-quality assets from AiLNP, AiRNA, and AiTEM platforms in the future, the company's NanoForge platform's value and commercial realization capabilities are expected to accelerate.